H
Honeybear Biosciences
Antibody drug conjugation platform advancing novel cancer therapeutics globally
About Honeybear Biosciences
HoneyBear Biosciences, Inc, established in 2021, is a Taiwan-based biotech company focused on the global pharmaceutical market. The company specializes in developing new antibody technologies aimed at delivering novel therapeutics to cancer patients. Utilizing its proprietary antibody drug conjugation platform, CoNectar, HoneyBear Biosciences is at the forefront of global drug development. The company's business model revolves around leveraging its powerful antibody engineering platforms to develop and commercialize novel Antibody Drug Conjugates (ADCs) through licensing and co-development partnerships with biotech and pharmaceutical companies. HoneyBear Biosciences aims to improve therapeutic outcomes for cancer patients by creating the next wave of effective anti-cancer medicines. The company serves biotech and pharmaceutical clients, operating in the global pharmaceutical market. Revenue is generated through partnerships and licensing agreements. The management team boasts diverse international experience in chemistry and biological sciences, combining innovative research with rigorous development expertise. Keywords: antibody, drug conjugation, cancer therapeutics, CoNectar, ADCs, licensing, partnerships, biotech, pharmaceutical, Taiwan.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Taipei, Taiwan
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Antibodies, Biotech and Pharma, Antibody-Drug Conjugate, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Honeybear Biosciences.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2026 | $20M | $80M | A*STAR | ↗ |
Growth signals
Latest recorded traffic for Honeybear Biosciences is 210 monthly website visits, down 46.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 IgualfanOral IgA antibody research and development for microbiome control |
Tokyo, Japan | Operational | — | $2.4M | $9.5M |
 Shizhiyuan BiotechnologyInnovative monoclonal antibody drug development and manufacturing |
China | Operational | |||
 Neologics BioscienceClinical-stage immuno-modulating antibody therapeutics for cancer |
Changzhou, China | Operational | |||
 Shengshi JunlianAI-driven discovery and optimization of macromolecular drugs |
Chengdu, China | Operational | |||
 Appfinder TherapeuticsAntibody drug development using proprietary screening platforms |
Anyang-si, South Korea | Operational | |||
 Dualitas TherapeuticsBispecific antibody therapies for immune and inflammatory diseases |
South San Francisco, United States | Operational | |||
 Adcoris BioPharmaNext-generation antibody-drug conjugates for oncology |
China | Operational | |||
 Minghui PharmaceuticalLate-stage biopharma developing therapeutics for cancer and immunology |
Ningbo, China | Operational |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
A*STAR
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Honeybear Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Honeybear Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.